Hopkinton, Mass., Sept. 24 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today introduced a series of XenoLight Rediject reagents at the World Molecular Imaging Congress (WMIC) in Montreal, Canada. Rediject D-Luciferin Ultra is the latest in an expanding range of XenoLight reagents for Caliper's IVIS optical imaging systems.
Rediject D-Luciferin Ultra is supplied in a ready-to-inject format, pre-formulated with a tracking agent in order to monitor injection quality and minimize data variability. Using this reagent in an IVIS imaging system, researchers can validate their techniques and generate more reproducible data in less time.
With over 750 IVIS instrument placements worldwide in the field, Caliper is widely recognized as the leader in the field of in vivo optical imaging. In the past year, Caliper has introduced two major imaging platforms including the IVIS Kinetic, which uses video-rate imaging to image biological processes in real-time, and the IVIS Lumina XR, Caliper's first instrument to integrate fluorescence, bioluminescence and x-ray capabilities into a single system. A bibliography of more than 1,000 peer-reviewed publications shows that IVIS systems are now employed by academic and commercial research organizations in all therapeutic areas, from oncology and infectious disease to stem-cell therapies, immunology and arthritis.
"Caliper is committed to partnering with our customers to provide not only innovative technology, but also the technical expertise necessary to ensure the best quality data," said Kevin Hrusovsky, CEO of Caliper Life Sciences. "The recent releases of IVIS Lumina XR and the XenoLight reagents show that we are responding to customer input in making optical imaging processes more convenient, multi-modal and integrated with the imaging techniques used in the clinic."
To make in vivo imaging routine and accessible for everyday research, Caliper distributes and supports a suite of aftermarket consumable products, including Bioware cell lines with both fluorescent and bioluminescent reporters, and XenoLight fluorescent labeling kits for proteins and antibodies. XenoLight DiR provides a fluorescent tracking dye to monitor stem cell migration, and the new family of Rediject substrates enable the detection of multiple luciferase reporters, including transgenic cell lines and BRET Q-Dots. XenoLight reagents exploit the unique combination of bioluminescent sensitivity and fluorescent spectral unmixing that characterizes the complete line of IVIS imaging systems.
For additional information on Caliper's portfolio of optical imaging systems, please visit http://www.caliperls.com/products/optical-imaging/.
About Caliper Life Sciences
Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.
Caliper, IVIS and Bioware are registered trademarks of Caliper Life Sciences. XenoLight and Rediject are unregistered trademarks of Caliper Life Sciences. Qdot nanocrystals is a registered trademark of Life Technologies Corporation.
|SOURCE Caliper Life Sciences, Inc.|
Copyright©2009 PR Newswire.
All rights reserved